NEW YORK — A new, higher-dose nasal spray for reversing opioid overdoses did not save more lives than the previous standard dose, but it did cause more vomiting and other side effects, researchers ...
A study comparing a new, higher-dose nasal spray for opioid overdoses to the standard dose found no increase in survival rates but more side effects. The 8-milligram naloxone spray, approved two years ...
U.S. regulators on Friday approved the first high-dose nasal spray for reversing opioid overdoses. The Food and Drug Administration approved Hikma Pharmaceuticals’ Kloxxado, a spray containing 8 ...
The discovery of the role of nicotinic receptors in attention and memory has led to the testing of nicotinic analogs as cognitive enhancing agents in patient populations. Empirical information about ...
Crystal Lake, Illinois-based Aptar Pharma ($ATR) launched technology designed to monitor dosing and adherence in its inhalers. It also teamed up with Adapt Pharma to ...
FILE - This image provided by Hikma Pharmaceuticals shows the company's nasal spray drug Kloxxado, containing 8 milligrams of naloxone. A study published Thursday, Feb. 8, 2024 finds that a new, ...
U.S. regulators on Friday approved the first high-dose nasal spray for reversing opioid overdoses. The Food and Drug Administration approved Hikma Pharmaceuticals’ Kloxxado, a spray containing 8 ...
NEW YORKNEW YORK — A new, higher-dose nasal spray for reversing opioid overdoses did not save more lives than the previous standard dose, but it did cause more vomiting and other side effects, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback